Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK9 | P45984 | 1/20 | 0.63 |
| ▸ | KDR | P35968 | 12/20 | 0.62 |
| ▸ | FLT1 | P17948 | 4/20 | 0.62 |
| ▸ | FLT4 | P35916 | 4/20 | 0.62 |
| ▸ | PIM1 | P11309 | 3/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.45 |
| ▸ | CTSC | P53634 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6986720 | 0.85 | MAPK9 (0.67) | MAPK9KDRFLT1FLT4PIM1 | |
| SCHEMBL6981902 | 0.81 | MAPK9 (0.62) | MAPK9KDRFLT1FLT4PIM1 | |
| SCHEMBL6982664 | 0.78 | MAPK9 (1.00) | MAPK9KDRFLT1FLT4PIM1 | |
| SCHEMBL7664658 | 0.77 | MAPK9 (0.61) | MAPK9PIM1MAPK10 | |
| SCHEMBL3894802 | 0.76 | KDR (1.00) | KDRFLT1FLT4 | |
| SCHEMBL6985864 | 0.74 | MAPK9 (0.94) | MAPK9KDRFLT1FLT4PIM1 | |
| SCHEMBL3896615 | 0.72 | KDR (1.00) | KDRFLT1FLT4 | |
| SCHEMBL5814307 | 0.71 | MAPK9 (0.46) | MAPK9PIM1CTSC | |
| SCHEMBL17207300 | 0.70 | KDR (0.56) | MAPK9KDRFLT1FLT4MAPK10 | |
| SCHEMBL6105422 | 0.70 | GSK3B (0.53) | MAPK9PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6579874-B2 | P38 MAP kinase inhibitors; treating Tumor necrosis factor (TNF-alpha) and Interleukin-1 mediated diseases, such as rheumatoid arthritis; imidazole and oxazole derivatives | NOVARTIS AG (CH) | 2003-06-17 | — | — | US | disclosed |
| US-20020049220-A1 | Substituted azoles | NOVARTIS AG (CH) | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049220-A1 | Substituted azoles | MAPK1, MAPK4, MAP3K1 | MAPK9 14/4885KDR 2023/4885FLT1 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.